Antigen-Specific airT Cells for Autoimmune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to treating autoimmune diseases with adoptive transfer of regulatory T cells face challenges such as lack of autoantigen specificity, uncontrolled cell plasticity, and difficulties in isolating and expanding antigen-specific Treg cells, leading to limited therapeutic efficacy.
Innovation Solution
Development of artificial antigen-specific immunoregulatory T cells (airT cells) engineered to express FOXP3 and antigen-specific T cell receptors, which are stable and maintain immunosuppressive function, allowing for targeted antigen-specific immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural regulatory T cells are used for adoptive transfer, then immunosuppressive function is provided, but lack of autoantigen specificity and uncontrolled cell plasticity limit therapeutic efficacy
Solution Approach 1:
The patent applies local quality by endowing T cells with specific local properties: engineered FOXP3 expression provides constitutive immunosuppressive function, while simultaneously introducing antigen-specific TCRs provides targeted recognition capability. This creates T cells with localized functional specialization - both suppressive and antigen-specific properties coexist in the same cell population, resolving the contradiction between reliability and adaptability
Solution Approach 2:
The invention creates composite T cells that combine properties of different cell types: the suppressive phenotype of regulatory T cells (via FOXP3 expression) is merged with the antigen-specific recognition capability of effector T cells (via TCR engineering). This composite cell structure achieves both constitutive immunosuppression and antigen-specificity, directly addressing the technical contradiction
2Productivity
If antigen-specific Treg cells are isolated from natural sources, then autoantigen specificity is achieved, but difficulties in isolating sufficient quantities and poor proliferation ability limit therapeutic application
Solution Approach 1:
The patent applies preliminary action by pre-engineering the desired properties (FOXP3 expression and antigen-specific TCR) into T cells before adoptive transfer. This eliminates the need for difficult post-isolation expansion and maintains both antigen-specificity and suppressive function from the outset, solving the productivity-manufacturability contradiction
Solution Approach 2:
The invention changes key parameters of T cells through genetic engineering: FOXP3 expression levels are modified to ensure constitutive suppressive function, and TCR specificity is altered to target autoantigens. These parameter changes create cells that are both easily manufactured (via viral transduction) and highly productive (sufficient quantities with maintained function)
3Quantity of substance
If Treg cells are expanded ex vivo, then sufficient cell numbers are obtained, but loss of immunosuppressive function and cell plasticity occur
Solution Approach 1:
The patent implements feedback control through engineered FOXP3 expression that maintains constitutive immunosuppressive function. The FOXP3 transcription factor acts as a molecular feedback mechanism that ensures stable expression of suppressive phenotypes even during ex vivo expansion, preventing loss of function while cell numbers increase
Solution Approach 2:
The invention applies beforehand cushioning by pre-engineering stability mechanisms into the T cells before expansion. The constitutive FOXP3 expression and antigen-specific TCR configuration are established in advance to cushion against the destabilizing effects of ex vivo expansion, maintaining functional stability throughout the expansion process
Data Source
AI summary
Some embodiments of the compositions and methods disclosed herein include gene-edited, artificial immunoregulatory T cells (airT cells) comprising a constitutively expressed FoxP3 gene product expressed at a level equal to or greater than the level of FoxP3 expression in natural T regulatory (Treg or suppressor T) cells, and a transduced (e.g., artificially engineered by gene editing, viral vector transduction, transfection or other genetic engineering methodologies) T cell receptor (TCR). In some embodiments, the TCR is preferably specific for an antigen associated with an autoimmune, allergic, or other inflammatory condition. Some embodiments include methods for the preparation and/or use of airT cells. Some such embodiments include use of airT cells for the treatment and/or amelioration of a disorder, in which antigen-specific immunosuppression may be beneficial, such as an autoimmune, allergic, or other inflammatory disorder.